Ohio's Opioid Suit Should Be Thrown Out, Purdue Pharma Argues
- Case targeting Oxycontin marketing flawed, according to filing
- Drugmaker contends FDA approval of painkiller bars state suits
Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah, on Aug. 31, 2016.
Photographer: George Frey/BloombergThis article is for subscribers only.
The state of Ohio’s lawsuit against opioid maker Purdue Pharma should be thrown out because it runs afoul of federal drug regulations and doesn’t show the company’s Oxycontin painkiller marketing caused specific harm, according to a court filing.
Stamford, Connecticut-based Purdue filed its response late Friday in state court in Ohio to Attorney General Mike DeWine’s May suit, accusing the pharmaceutical firm and four other opioid makers of using misleading marketing to dupe doctors into over-prescribing opioids.